The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma

Our results support the relationship between microbiota and CAR T-cell therapy major outcomes. Analysis of microbiota led to the identification of SCFAs, especially butyrate, as a prognostic factor, and also provides the basis for considering them as chemical modifiers of CAR T cells to improve their efficacy.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-11-13
DOI
https://doi.org/10.1158/1078-0432.ccr-25-1676
Citations
1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma

Alba Rodríguez-García, Javier Modrego, Dulcenombre Gómez‐Garré, José María Sánchez‐Pina et al.
1 citations
Clinical Cancer Research
CAR-T cell therapy research
1.05
article

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma

Alba Rodríguez-García, Javier Modrego, Dulcenombre Gómez‐Garré, José María Sánchez‐Pina, Irene Bragado-García, Ana Jiménez Ubieto, María Linares, Francisco Abraham Tomás-Barberán, Joaquín Martínez‐López, Mariana Bastos‐Oreiro, Diego Carbonell, Andrés Arroyo, Pere Barba, Miguel Ángel Navarro-Aguadero, Alejandro Martı́n, Cecilia Carpio, Mi Kwon, María‐Teresa Cedena, María Hernández‐Sánchez, Adriana Ortega‐Hernández, Alejandra Ortiz-Ruiz, Alejandra Leivas, Rocío Garcı́a-Villalba, Raquel Ancos-Pintado, Roberto García-Vicente, Rafael Alonso Fernández, Eva Castellano, Antonio Valeri
article en
1 citations

Abstract

Our results support the relationship between microbiota and CAR T-cell therapy major outcomes. Analysis of microbiota led to the identification of SCFAs, especially butyrate, as a prognostic factor, and also provides the basis for considering them as chemical modifiers of CAR T cells to improve their efficacy.

Clinical Cancer ResearchVol. 32(2)
Universidad Complutense de Madrid (ES), Hebron University (PS), Universitat Autònoma de Barcelona (ES), Universidad de Salamanca (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Clínico San Carlos (ES), Research Institute Hospital 12 de Octubre (ES), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), Hospital Universitario 12 De Octubre (ES), Vall d'Hebron Institut de Recerca (ES), Centro de Edafología y Biología Aplicada del Segura (ES), Centro Nacional de Epidemiología (ES), Centro de Investigación Biomédica en Red (ES), Unidades Centrales Científico-Técnicas (ES), Instituto de Investigación Biomédica de Salamanca (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Vall d'Hebron Institute of Oncology (ES), Universidad Politécnica de Madrid (ES)
Openalex Percentile: Top 16%
CAR-T cell therapy research
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.